We describe a double-antibody radioimmunoassay for apolipoprotein B with use of monoclonal antibodies. Values for 32 patients with various lipid disorders, obtained with use of one of the monoclonal antibodies (464B1 B6), were similar to those obtained with use of a polyclonal antiserum. When we used another monoclonal antibody (465C3D1) the values were significantly lower. Monoclonal antibody 464B1 B6 recognized apolipoprotein B determinants in the very-low-density-lipoprotein and low-density-lipoprotein fractions of plasma in a similar fashion as in unfractionated plasma, but monoclonal 465C3D1 gave lower values with the fractionated plasma. For precipitation of the antibody-apolipoprotein complex to be complete, use of polyethylene glycol was necessary with one of the monoclonal antibodies but not with the other. The interassay CV was 12.3% and 11.6% for the assays with the monoclonal antibodies. Analytical recoveries ranged from 85 to 94%. Owing to variations in the 650 from one preparation of standard to another, we found it necessary to normalize the results to those of a serum pool. We conclude that certain monoclonal antibodies can be used effectively in radioimmunoassays for apolipoprotein B in plasma and may help in the standardization of these assays.
epitopes of apolipoprotein B. Monoclonal antibodies developed in our laboratories (10-13) and in others (14-21) have been used to study isolated LDL and apolipoprotein B molecules, with emphasis on elucidating the structure of the molecule. We were interested in assessing the use of monoclonal antibodies in radioimmunoassays to measure apolipoprotein B in the plasma of hyperlipidemic patients. A double-antibody RIA involving polyclonal antisera against LDL has been in use in one of our laboratories (G.S.) for many years (22) . A comparison of the apolipoprotein B values obtained with monoclonal antibodies with those from this polyclonal-antisera assay demonstrated that certain monoclonal antibodies may indeed be useful for measuring total apolipoprotein B, but that other monoclonal antibodies may measure only part of that species in plasma.
During our preparation of this manuscript, Patton et al. (23) published results of a RIA in which a monoclonal antibody was used to measure apolipoprotein B in patients with coronary heart disease.
Materials and Methods

Reagents
Production and affinity purification of two anti-LDL monoclonal antibodies (464B1B6 and 465C3D1) have been described previously (10). A rabbit anti-LDL polyclonal antibody (R198-2) and purified LDL (d 1.025-1.050) were prepared as previously described (22) and stored at 4#{176}C. The apolipoprotein B content of the purified LDL preparations was evaluated by measuring the protein by the classical method of Lowry et al. A serum pool was prepared from excess serum submitted for routine chemical analysis at Barnes Hospital and stored in aliquots at -70 #{176}C. A commercial product (Omega'TMLipid Fraction; Hyland Diagnostics, Deerfield, IL 60015), used as a quality-control material, was stored lyophilized at 4#{176}C. Plasma samples from patients seen at the Lipid Research Clinic were collected in 10-mL Vacutainer Thbes containing tri-potassium EDTA and centrifuged at room temperature. The plasma was stored at 4#{176}C and assayed within a month. Na1251 was purchased from Amersham, Arlington Heights, IL 60005; Iodo-gen" from Pierce Chemical Co., Rockford, IL 61105; bovine serum albumin (Cohn Fraction V) from U.S. Biochemicals, Cleveland, OH 44122; and nonimmune sera and second antibodies from Pel-Freeze, Rogers, AR 72756. All other chemicals, including polyethylene glycol (Mr 8000), were from Sigma Chemical Co., St. Louis, MO 63178. lodination of LDL Purified LDL was iodinated by a modification of the method involving 1,3,4,6-tetrachloro-3a,6a-diphenylglycouril (lodo-gen) (24) . We mixed 15-25 pg of LDL in 200 L of 0.25 molIL Tris HC1, pH 7.6, at room temperature with 0.5 mCi of Na'251 and transferred the mixture to a polypropylene tube precoated with 100 p.g of lodo-gen. The tubes were each coated with 100 L of 1 g/L lodo-gen solution in chloroform, the chloroform then being evaporated under a stream of nitrogen. The reaction was allowed to proceed at 
Radioimmunoassay
A double-antibody radioimmunoassay was developed based on competition between '251-labeled LDL and unlabeled LDL (standard or sample) for a monoclonal or polyclonal antibody. The selected dilution of the primary antibody was based on the amount of antibody necessary to precipitate the maximum radioactivity (i.e., number of counts).
Initially
we used a dilution of primary antibody that precipitated 50 to 60% of the radioactivity. This assay was more sensitive but less precise than the final assay. Because sensitivity was not a problem, we used the higher amount of primary antibody. The concentration of the second antibody was then re-titered, to ensure maximum precipitation. The 1251-labeled LDL was more than 90% precipitated with polyclonal antiserum R198-2 and monoclonal antibody 464B1B6, but only 20-25% of the counts were precipitated with monoclonal antibody 465C3D1. These results were the same whether or not non-immune mouse serum (0.3 mLIL) was present. We then assessedthe influence of polyethylene glycol on the precipitability of labeled LDL in the presence and absence of antibody 465C3D1. We selected a concentration of polyethylene glycol that caused precipitation of >90% of the labeled LDL with <2% increase in nonspecific binding. The degree of dilution of the samples was such that the average sample would displace 50% of the available counts (B). The minimum time required for the primary antibody reaction to reach equilibrium was 16 h at 4#{176}C or 2 h at 37#{176}C. For the second-antibody reaction, equilibrium was reached after 16 h at 4#{176}C or 2 h at 37 #{176}C. The time and temperature for the final assay conditions were chosen to ensure equilibrium and to provide technical flexibility. Under the final assay conditions, dilutions of the serum pool produced displacement curves paralleling those of the LDL standard for all three antibodies. Dilutions of plasma samples also paralleled the LDL standard curves, but we did not run complete displacement curves on every sample. Table 1 details final assay conditions for the two monoclonal antibodies and one polyclonal antisera. The assays were performed in polystyrene tubes, and the assay buffer was sodium barbital (0.1 molJL, pH 8.3) containing lOg of bovine serum albumin and 1 mmol of Na2EDTA per liter. The assays were performed in duplicate as follows:
1. '251-labeled LDL, 36000-40 000 counts/mm, in 100 L of assay buffer was added to each tube.
2a. 50 L of assay buffer containing no standard or sample was added to establish the maximum amount of counts bound (B0).
2b. 50 L of assay buffer containing no standard or sample was added to establish the nonspecific binding (NSB). 6. The tubes were incubated for 2 h at 37 #{176}C. We then added 1 mL of assay buffer to all tubes and pelleted the precipitated LDL-antibody complex by centrifugation (3000 x g, 25 mm). The pellet was washed with 1 mL of assay buffer and the pellet recentrifliged and its radioactivity counted. Data reduction included subtraction of NSB counts from the counts of each tube, averaging of duplicates, and calculation of B/B0 for each dose of standard, control or sample. Typical standard curves are shown in Figure 1 . The concentrations of apolipoprotein B in control and sample were determined from a logit transformation of the standard curve (done with software available in the gamma counter).
We occasionally saw considerable variation in values for the serum pool and the Omega quality-control material LDL value of unknown x (100/LDL value of serum pool) = N.UJdL
The average value for the serum pool used for normalization was determined in the polyclonal assay to be 173.4 mg/ dL, a much higher value than generally reported by others and by one of us previously (22) . We believe this is ascribable to the particular LDL preparation from different individuals that we used to prepare the standard curves during this study. A second serum pool prepared and assayed more recently with different LDL standard preparations had an ApeB value of 116 mg/dL when assayed with 464B1B6 and 120 mg/dL when assayed with a polyclonal antibody with use of the same LDL standards. When analyzed in the same assay (antibody 464B1B6), the two serum pools give indistinguishable ApeB values. The commercial quality-control material, Omega Lipid Fraction, was specified by the manufacturer to have a mean Ape B value of 64 mg/dL. The values we obtained after normalization to the initial serum pool were 69.9-71.0 N.UJdL with the three antibodies. More recently we assayed the same quality-control material with 464B1B6 and normalized with the second serum pool, obtaining a value of 74.3 (SD 4.6) N.UJdL, not statistically different from the values with the initial serum pool.
In addition to whole plasma, we fractionated several plasma samples by differential density centrifugation into a VLDL and an LDL + HDL fraction. The apolipoprotein B values for the fractions were determined and compared with the values for whole plasma.
Cholesterol and triglyceride were determined by the standardized methods used in the Lipid Research Clinic protocols.
Analytical-recovery experiments were performed by supplementing the serum pool with known amounts of purified LDL and measuring the difference in measured apolipoprotein B concentration in supplemented and unsupplemented serum. Percentage recovery was calculated as (amount recovered/amount added) x 100. Precision was assessed by measuring the control sera or patients' samples repeatedly in the same assay or in multiple assays done during several weeks. The stability of patient samples was assessed by measuring the sample on the day it was drawn and then periodically re-assaying aliquots stored at 4 or -70 #{176}C for up to 60 days. The change in values for samples assayed in 10-day intervals was assessed by the Wilcoxin signed ranked test.
Results
Precision, Recovery, and Stability
Precision data for the assay are shown in Table 2 . The interassay precision (CV) for the various assays as assessed by use of the Omega control was 15-20%; for patients' samples it was 12-21%. The assays in which monoclonal antibodies were used were substantially more precise than when polyclonal antisera were used.
Analytical recovery in assays involving monoclonal antibodies was 85-94%, which compares well with the 89.8% recovery for polyclonal antisera.
The stability of 39 plasma samples was assessed by periodically assaying patients' samples that had been stored at 4 or -70 #{176}C for various intervals up to 60 days. The values obtained with antibodies R198-2 or 465C3D1 showed no statistically significant deterioration with either storage temperature. The samples analyzed with antibody 464B1B6 gave lower results after 30 days at -70 #{176}C but were stable if kept at 4#{176}C. For this reason we routinely store the plasma samples at 4#{176}C and analyze them within 30 days.
Apolipoprotein B Values for Patients
Plasma samples were obtained from 32 patients with various lipid disorders (12 with Type ila, 11 with Type lIb, three with Type ifi, five with Type 1V, and one with Type V). In Figure 2 we compare apolipoprotein B values obtained with the three antibodies. The line equations were determined by use of the linear function slope-estimation technique, an alternative to the least-squares regression technique that does not require the assumption that one of the methods is error free (25) . The values obtained with the monoclonal antibodies correlated well with each other and with the polyclonal antisera. However, using the Wilcoxon signed rank test, we found that the values of samples obtained with the monoclonal antibodies differed significantly from each other and from the polyclonal assay values. This difference was not observed for the quality-control material ( Table 2 We have developed reliable double-antibody RIAs for apolipoprotein B in which monoclonal antibodies are used. With one of the antibodies, use of polyethylene glycol was necessary to ensure complete precipitation; with the other, polyethylene glycol was not necessary. Because the monoclonal antibodies bind at one epitope, the antigen-antibody complex is smaller than that obtained with polyclonal antisera unless the epitope is repeated in the molecule. Therefore it is not surprising that polyethylene glycol may be necessary for complete precipitation.
Our experience suggests that polyethylene glycol should be tried whenever a low percentage of counts are found in double-antibody RIA with use of monoclonal antibodies. We found that nonmmune serum was not needed in our assays.
The monoclonal antibodies we utilized in our assay were from seven that have been developed to five different epitopes of LDL (10-13). The two antibodies chosen have both shown reactivity to the B-100 and B-74 forms (11) of apolipoprotein B found in LDL. In addition, antibody 464B1B6 has reactivity to the B-26 form found in LDL and to the B-48 form found in the VLDL fraction, but not to the chylomicron fraction. This antibody also inhibits binding of LDL to fibroblasts. The binding of both antibodies correlates only weakly, if at all, with the phospholipid content of the LDL. Because of these reactivities it is attractive to attribute the difference in values between antibodies 465C3D1 and 464B1B6 to the amount of B-26 and B-48 lipoprotein present in the samples, but this has not been established. Alternative explanations include conformational differences of the epitopes in plasma. Both antibodies bind less avidly if the lipid of LDL is extracted and 465C3D1 is more reactive to chemically modified LDL. In addition, antibody 464B1B6 reacts more avidly with apolipoprotein B from LDL than VLDL (11). Both antibodies produced parallel displacement to LDL isolated from 17 individuals with serum cholesterol values ranging from 121 to 454 mg/dL, but the epitopes expressed relative to the standard preparation were more variable with antibody 465C3D1 (12). Interestingly, a lyophilized quality-control material did not show any difference in apolipoprotein B values by the three antibodies (Table 2) . This is probably due to the loss of some epitopes during the preparation of the control material and reemphasizes the need for work with fresh human samples when developing immunoassays.
The specificity of these antibodies to various lipoprotein (10-13) . Their specificity in plasma appears good, as judged by the correlation of results with a polyclonal antisera and total cholesterol and lack of correlation with triglyceride.
A major problem with all of the assays was their reproducibility. This variability correlated with changes in the B50,suggesting that variations in the LDL standard were responsible. This assumption is further supported by the assay of a second serum pool in two different laboratories by different antibodies (464B1B6 and a polyclonal) but the same standard LDL preparation. The values obtained with the different antibodies were 116 and 120 mg/dL, respectively, which is lower than reported for the serum pool used in this work. However, when the serum pools were analyzed in the same assay, the Apo B values were indistinguishable. We have used a narrow density band of LDL (d 1.025-1.050 kg/L), which is freshly prepared every four weeks as standard and tracer. A mild iodination scheme was used and the tracer repurifled before each assay. Nevertheless, we, like others working with apolipoproteins (9, 26, 27), have had to utilize a secondary standard to obtain reproducible results. This problem appears related to the unique biochemical properties of apolipoproteins rather than to the monoclonal antibodies.
In conclusion, we have shown that monoclonal antibodies can be used for the measurement of apolipoprotein B in plasma and that differences in the epitopes measured can lead to different values for the antigen. We are now performing studies to establish the clinical utility of measuring apolipoprotein B with monoclonal antibodies.
